NASDAQ : PRLD
Prelude Therapeutics Incorporated — Key statistics
Healthcare · Biotechnology · United States
Last price 4.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 422.28M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 395.50M |
| Enterprise Value | 261.39M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 65.08M |
| Shares Outstanding | 102.99M |
| Shares Change (YoY) | +10.91% |
| Shares Change (QoQ) | +19.23% |
| Owned by Insiders (%) | 4.38% |
| Owned by Institutions (%) | 20.25% |
| Float | 22.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.68 |
| Forward PS | 7.74 |
| PB Ratio | 2.99 |
| P/TBV Ratio | 2.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 11.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.07 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -57.73% |
| Return on Assets (ROA) | -27.15% |
| Return on Invested Capital (ROIC) | -33.70% |
| Return on Capital Employed (ROCE) | -43.68% |
| Weighted Average Cost of Capital (WACC) | 9.13% |
| Revenue Per Employee | $283,848 |
| Profits Per Employee | -$765,671 |
| Employee Count | 79 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +140.88% |
| 50-Day Moving Average | 4.40 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 47.72 |
| Average Volume (20 Days) | 427,571 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.10M |
| Short Previous Month | 4.58M |
| Short % of Shares Out | 4.95% |
| Short % of Float | 23.10% |
| Short Ratio (days to cover) | 10.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 22.42M |
| Gross Profit | 22.42M |
| Operating Income | -66.10M |
| Pretax Income | -60.49M |
| Net Income | -60.49M |
| EBITDA | -64.51M |
| EBIT | -66.10M |
| Loss Per Share | -$0.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 151.76M |
| Total Debt | 17.65M |
| Net Cash | 134.11M |
| Net Cash Per Share | $1.30 |
| Equity (Book Value) | 133.73M |
| Book Value Per Share | 1.30 |
| Working Capital | 116.86M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -33.26M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.59M |
| Net Borrowing | n/a |
| Free Cash Flow | -33.26M |
| FCF Per Share | -$0.32 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -294.76% |
| Pretax Margin | -269.75% |
| Profit Margin | -269.75% |
| EBITDA Margin | -287.68% |
| EBIT Margin | -294.76% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.91% |
| Shareholder Yield | -10.91% |
| Earnings Yield | -18.71% |
| FCF Yield | -8.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.20 |
| Price Target Difference | 139.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 101.96% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.26 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |